Pharmaceutical and Healthcare disease pipeline guide Actinic (Solar) Keratosis – Pipeline Review, H1 2017, provides an overview of the Actinic (Solar) Keratosis (Dermatology) pipeline landscape.
An actinic keratosis, also known as a solar keratosis, is a scaly or crusty growth (lesion). It most often appears on the bald scalp, face, ears, lips, backs of the hands and forearms, shoulders, neck or any other areas of the body frequently exposed to the sun. The signs and symptoms of an actinic keratosis include a hard, wart-like surface, patch or bump on the top layer of skin, itching or burning in the affected area and color as varied as pink, red or brown, or flesh-colored. The predisposing factors include age, sunny climate, history of frequent or intense sun exposure or sunburn, pale skin, red or blond hair, and blue or light-colored eyes and a weak immune system as a result of chemotherapy, chronic leukemia, AIDS or organ transplant medications.
Pharmaceutical and Healthcare latest pipeline guide Actinic (Solar) Keratosis – Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Actinic (Solar) Keratosis (Dermatology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Actinic (Solar) Keratosis (Dermatology) pipeline guide also reviews of key players involved in therapeutic development for Actinic (Solar) Keratosis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 3, 6, 1, 6, 1 and 3 respectively. Similarly, the Universities portfolio in Phase II stages comprises 1 molecules, respectively.
Actinic (Solar) Keratosis (Dermatology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
– The pipeline guide provides a snapshot of the global therapeutic landscape of Actinic (Solar) Keratosis (Dermatology).
– The pipeline guide reviews pipeline therapeutics for Actinic (Solar) Keratosis (Dermatology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
– The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
– The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
– The pipeline guide reviews key companies involved in Actinic (Solar) Keratosis (Dermatology) therapeutics and enlists all their major and minor projects.
– The pipeline guide evaluates Actinic (Solar) Keratosis (Dermatology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
– The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
– The pipeline guide reviews latest news related to pipeline therapeutics for Actinic (Solar) Keratosis (Dermatology)
Reasons to buy
– Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
– Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
– Find and recognize significant and varied types of therapeutics under development for Actinic (Solar) Keratosis (Dermatology).
– Classify potential new clients or partners in the target demographic.
– Develop tactical initiatives by understanding the focus areas of leading companies.
– Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
– Formulate corrective measures for pipeline projects by understanding Actinic (Solar) Keratosis (Dermatology) pipeline depth and focus of Indication therapeutics.
– Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
– Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Content: Key Points
List of Tables
List of Figures
Actinic (Solar) Keratosis – Overview
Actinic (Solar) Keratosis – Therapeutics Development
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Actinic (Solar) Keratosis – Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Actinic (Solar) Keratosis – Companies Involved in Therapeutics Development
3M Drug Delivery Systems
Foamix Pharmaceuticals Ltd
G&E Herbal Biotechnology Co Ltd
Laboratories Ojer Pharma SL
LEO Pharma A/S
Oncology Research International Ltd
Promius Pharma LLC
Valeant Pharmaceuticals International Inc
Partner Relations & Marketing Manager
Ph: +1-646-845-9349 (US)
Ph: +44 208 133 9349 (UK)
Get in touch: